Oncology Pharma : Financial Statements for the period ended December 31, 2021

ONCOLOGY PHARMA, INC.

QUARTERLY REPORT

FINANCIAL STATEMENTS

-UNAUDITED-

FOR THE NINE MONTHS ENDED

DECEMBER 31, 2021

Oncology Pharma, Inc.
Balance Sheets
(Unaudited)
	As of			As of
	December 31, 2021		March 31, 2021
ASSETS
CURRENT ASSETS
Cash	$	29,004	$	8,954
Total Current Assets		29,004			8,954
INVESTMENTS
Investment in NanoSmart Pharmaceuticals, Inc. Licensing Agreement		326,350			76,350
Investment in KCL Therapeutics, Inc. Licensing Agreement		1,400,000			-
Investment in Regen Biopharma, Inc. Licensing Agreement		55,000			-
Investment in Sybleu, Inc. Licensing Agreement		237,250			237,250
Investment in Kalos Therapeutics, Inc. Licensing Agreement		-			-
Investment in Ribera Solutions, LLC Licensing Agreement		75,000			25,000
Total Investments		2,093,600			338,600
FIXED ASSETS
Furniture, net		-			-
Total Fixed Assets		-			-
TOTAL ASSETS	$	2,122,604	$	347,554
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Accounts Payable and Accrued Expenses	$	199,329	$	279,181
Loans Payable Related Party		96			885
Convertible Notes Payable Related Party		3,550			3,550
Promissory & Convertible Notes Payable		647,590			233,950
Total Current Liabilities		850,565			517,566
TOTAL LIABILITIES	$	850,565	$	517,566
STOCKHOLDERS' EQUITY ((DEFICIT)
Preferred Series A stock, $0.001 par value,		1,000			1,000
100,000,000 shares authorized, 1 share issued
and outstanding at September 30, 2021 and September 30, 2020
Common stock, $0.001 par value, 900,000,000		188,894			182,469
shares authorized, 33,763,216 and 27,338,216
issued and outstanding at December 31, 2021 and
March 31, 2021
Additional Paid In Capital		273,156,246			167,118,839
Retained Deficit		(272,074,102)			(167,472,319)
Total Stockholders' Equity (Deficit)		1,272,038			(170,012)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	2,122,604	$	347,554
The accompanying Notes are an integral part of these financial statements

Oncology Pharma, Inc. Statements of Operation (Unaudited)

	For the Nine Months Ended	For the Nine Months Ended
			December 31, 2021			December 31, 2020
Revenues	$	-		$	-
Costs and Expenses						-
General and Administrative			51,161			14,380,543
Depreciation			-			779
Total Operating Expenses			51,161			14,381,322
Operating Loss			(51,161)			(14,381,322)
Other Income and Expenses
Gain from license fee settlement			54,167			-
Interest Expense			(104,604,788)			(1,259,888)
Loss from Abandonment of Mining Claims and Licenses			-			(249,121)
Total Other Income and Expenses			(104,550,621)			(1,509,009)
Net Loss Before Taxes			(104,601,782)			(15,890,331)
Income Taxes			-			(3,494)
Net Loss	$	(104,601,782)		$	(15,893,825)
Net Loss Per Common Share (Basic and Diluted)	$	(3.42)		$	(1.19)
Weighted Average Common Shares Outstanding (Basic and Diluted)			30,550,716			13,349,197

The accompanying Notes are an integral part of these financial statements

Oncology Pharma, Inc. Statements of Cash Flow (Unaudited)

	For the Nine Months Ended	For the Nine Months Ended
		December 31, 2021		December 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(104,601,782)		$	(15,893,825)
Adjustments to reconcile net loss to
cash used in operating activities
Depreciation			-			779
Gain from legal settlement			(54,167)
Issuance of common stock for services						14,222,527
Issuance of common stock for interest expense			104,691,600			1,260,000
Changes in operating assets and liabilities
Accounts payable and accrued expenses			(79,852)			107,088
Loans and notes payable			412,851
Loss from abandonment of mining claims and licenses			-			249,121
NET CASH (USED) PROVIDED IN OPERATING ACTIVITIES			368,650			(54,310)
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in Licensing Agreements			(1,755,000)			(59,700)
NET CASH (USED) PROVIDED FROM INVESTING ACTIVITIES			(1,755,000)			(59,700)
CASH FLOWS FROM FINANCING ACTIVITIES
Common stock issued for license agreements			1,400,000			34,500
Increase in related party debt						6,490
Conversion of notes payable to common stock			6,400
Stock option grant for license agreement						25,000
Issuance of Convertible Notes Payable						48,200
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES			1,406,400			114,190
NET CHANGE IN CASH			20,050			180
CASH AT BEGINNING OF PERIOD			8,954			1,805
CASH AT END OF PERIOD	$	29,004		$	1,985
SUPPLEMENTARY INFORMATION
Stock issued for debt	$	6,400		$	-

The accompanying Notes are an integral part of these financial statements

Oncology Pharma, Inc.

Statements of Shareholders' Equity (Deficit) (Unaudited)

Statements of Changes in Stockholder's Deficit

For the Nine Months Ended December 31, 2021 and 2020

		Common Stock	Preferred Stock			Additional		Accumulated	Subscriptions
		Shares				Amount		Shares			Amount		Paid-in-Capital			Deficit			Receivable		Total
Balance as at March 31, 2020	1,501,461		$	150,146	1,000	$	1,000	$	69,784,384	$	(69,999,194)	$	-	$	(63,664)
Share rounding due to reverse stock split	217
Shares issued for services	20,580,038				22,066							14,200,461								14,222,527
Shares issued for licensing rights	50,000				5,000							32,500								37,500
Shares issued for debt conversion	3,000,000				3,000							1,257,000
Shares to be issued					50							34,450
Share option grant for licensing rights													25,000
Net Income (Loss) for period ending December 31, 2020																	(15,893,825)				(15,893,825)
Balance as at December 31, 2020		25,131,716		$	180,262	1,000	$	1,000	$	85,333,795	$	(85,893,019)	$	-	$	(377,962)
Balance as at March 31, 2021	27,338,216		$	182,469	1,000	$	1,000	$	167,118,838	$	(167,472,319)		-	$	(170,012)
Shares issued for licensing rights	50,000				50							1,399,950								1,400,000
Shares issued for debt conversion	6,400,000				6,400							104,691,600							104,698,000
Shares cancelled in legal settlement	(25,000)			(25)							(54,142)								(54,167)
Net Income (Loss) for period ending December 31, 2021																	(104,601,783)			(104,601,783)
Balance as at December 31, 2021		33,763,216		$	188,894	1,000	$	1,000	$	273,156,246	$	(272,074,102)		-		1,272,038

The accompanying Notes are an integral part to these financial statements.